ArticleEMBO molecular medicine2017
Synergistic antibacterial effect of silver and ebselen against multidrug-resistant Gram-negative bacterial infections.
Article in EMBO molecular medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 77 citations in OpenAlex.
- Linking oxidative stress defense to biofilm architecture: Ohr mediates strain-dependent persistence inVirulence · 2026Article
- Ebselen restores mitochondrial function through metabolic rewiring in Barth syndrome and related mitochondrial diseases.EMBO molecular medicine · 2026Article
- Dual Redox Targeting by Pyrroloformamide A and Silver Ions Enhances Antibacterial and Anti-Biofilm Activity Against Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Synthetic and semi-synthetic antioxidants in medicine and food industry: a review.Frontiers in pharmacology · 2025Review
- Ebselen: A Promising Repurposing Drug to Treat Infections Caused by Multidrug-Resistant Microorganisms.Interdisciplinary perspectives on infectious diseases · 2024Review
- Enhance the Antimycobacterial Activity of Streptomycin with Ebselen as an Antibiotic Adjuvant Through Disrupting Redox Homeostasis.Drug design, development and therapy · 2024Article
- Characterization and transmission of plasmid-mediated multidrug resistance in foodborneFrontiers in microbiology · 2024Article
- Insights into the Synergistic Antibacterial Activity of Silver Nitrate with Potassium Tellurite againstMicrobiology spectrum · 2023Article
- Inhibition of H1N1 Influenza Virus-induced Apoptosis by Ebselen Through ROS-mediated ATM/ATR Signaling Pathways.Biological trace element research · 2023Article
- Disruption of Bacterial Thiol-Dependent Redox Homeostasis by Magnolol and Honokiol as an Antibacterial Strategy.Antioxidants (Basel, Switzerland) · 2023Article
- Antibacterial Activity of Ebselen.International journal of molecular sciences · 2023Review
- Ebselen Optimized the Therapeutic Effects of Silver Nanoparticles for Periodontal Treatment.International journal of nanomedicine · 2023Article
- The Role of the Thioredoxin System in Brain Diseases.Antioxidants (Basel, Switzerland) · 2022Review
- Antimicrobial Activity Enhancers: Towards Smart Delivery of Antimicrobial Agents.Antibiotics (Basel, Switzerland) · 2022Review
- Adaptive Responses ofAntimicrobial agents and chemotherapy · 2022Article
- The synergistic activity of SBC3 in combination with Ebselen againstFrontiers in pharmacology · 2022Article
- The Assessment on Synergistic Activity of Ebselen and Silver Ion AgainstFrontiers in microbiology · 2022Article
- Conjugation of Silver Nanoparticles With De Novo-Engineered Cationic Antimicrobial Peptides: Exploratory Proposal.JMIR research protocols · 2021Article
- Ebselen and Analogues: Pharmacological Properties and Synthetic Strategies for Their Preparation.Molecules (Basel, Switzerland) · 2021Review
- Depletion of multidrug-resistant uropathogenic Escherichia coli BC1 by ebselen and silver ion.Journal of cellular and molecular medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multidrug-resistant (MDR) Gram-negative bacteria account for a majority of fatal infections, and development of new antibiotic principles and drugs is therefore of outstanding importance. Here, we report that five most clinically difficult-to-treat MDR Gram-negative bacteria are highly sensitive to a synergistic combination of silver and ebselen. In contrast, silver has no synergistic toxicity with ebselen on mammalian cells. The silver and ebselen combination causes a rapid depletion of glutathione and inhibition of the thioredoxin system in bacteria. Silver ions were identified as strong inhibitors of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.